Vertical AI Content for “ophthalmologist”
An AI writing, imagery and SEO content workflow for a hot vertical, on subscription.
Anchored on Google Trends keyword "ophthalmologist" · Auto-generated by deterministic model, not manual due diligence · Narrative prose was generated in Chinese; framework labels are localized.
Executive Summary
让美国用户 24/7 获得权威眼科初诊建议与预约,无需人工介入。
AI 驱动的眼科初筛与预约平台
AI 医疗合规进步,远程健康需求激增,搜索量同比增长 50%。
Source Hot Keyword
This plan anchors on a single top-ranked Google Trends keyword and derives from it the highest-ROI fully-online (web service) opportunity. The table below is the full provenance snapshot of that source keyword (stored with the plan and auditable).
| Source keyword | ophthalmologist |
| Collection rank | — |
| Search volume | 200 |
| Growth rate | +50% |
| Trend persistence | persistence: Flash trend (1 observations over 1 day) |
| Commercial intent | intent: Informational (6/10) |
| Category | Health |
| Region | US |
| Collected at | 07/29/2026, 04:02 PM |
| Source table | trending_now |
Opportunity Selection & Ranking
This plan auto-brainstorms from recent Google Trends keywords and ranks them with a transparent ROI model, selecting the fully-online (web service) opportunity with the highest return on investment.
| Rank | Opportunity | ROI score | One-line positioning |
|---|---|---|---|
| 1 | OphthaAI:全自动眼科健康在线服务 | 5.31 | 让美国用户 24/7 获得权威眼科初诊建议与预约,无需人工介入。 |
Supporting trend evidence (sample)
Problem
眼科医生稀缺,预约难、初筛慢,患者信息分散。
Solution
AI 自动问诊、初筛、预约与健康档案管理,提升就医效率。
AI 问答与初步症状评估
自动匹配附近眼科医生并预约
个性化健康档案与提醒
7x24 全天候 AI 客服
Market Analysis
TAM: $45B(US 眼科医疗市场,Grand View Research 2023)
SAM: $2.2B(在线初筛与预约,假设 5% TAM)
SOM: $11M(首年目标市场份额,0.5% SAM)
眼科初筛线上化率低,增长空间大。
Product & Service
AI 问答与初步症状评估
自动匹配附近眼科医生并预约
个性化健康档案与提醒
7x24 全天候 AI 客服
Business Model & Unit Economics
AI 初筛+预约 · $19/次 · AI 问诊、报告与医生预约
健康档案订阅 · $49/年 · 档案管理、定期提醒、AI 咨询不限次
单次服务边际成本 <$0.50(API+云),毛利率 >95%。
| Financial metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Active users | 3,609 | 10,026 | 20,052 |
| Paying users | 94 | 261 | 521 |
| Revenue (¥) | ¥211,162 | ¥586,310 | ¥1,170,374 |
| Gross profit (¥) | ¥173,153 | ¥480,775 | ¥959,707 |
| Opex (¥) | ¥604,675 | ¥975,592 | ¥1,399,614 |
| EBITDA (¥) | ¥-431,523 | ¥-494,818 | ¥-439,907 |
Unit economics: LTV $768 · effective CAC $224 · LTV/CAC 3.42:1 (healthy ≥3:1, credible cap 6:1) · payback 10.53 months · avg lifetime 3 years.
Year-3 indicative exit EV ≈ ¥0 (at 4× SDE/EBITDA, online-asset M&A benchmark).
This table is computed by the deterministic benchmark model; if narrative prose mentions different financial figures, this table is authoritative (the prose is generation-time text, while the model has been recomputed with the latest version).
Seed Return Analysis
1. Seed-round ROI by year (realized)
| Holding period | Cumulative ROI | Annualized return |
|---|---|---|
| Year 1 | -69.49% | -69.49% |
| Year 2 | -44.48% | -25.49% |
| Year 3 | -23.98% | -8.73% |
| Year 4 | -6.56% | -1.68% |
| Year 5 | 8.25% | 1.60% |
Early-stage equity is highly illiquid; negative realized returns in years 1–2 are normal (the classic J-curve), with returns realized via exit events in years 3–5.
2. Core investment metrics
3. 5-year capital outcome breakdown (why "cash realized" ≠ "paper alive")
| Outcome | Probability | Realized return to investor |
|---|---|---|
| Failure / liquidation | 27.4% | ≈ 0 (loss) |
| Alive but no liquidity event (paper-alive / zombie) | 40.4% | ≈ 0 (not realizable) |
| Cash exit event occurred (profitable exits 20.9%) | 32.2% | Realized per MOIC distribution |
Win rate counts only "cash exit with MOIC≥1"; paper survival is excluded, so it reflects the real probability of getting cash back.
4. Sensitivity analysis
| Scenario | 5-yr ROI | 5-yr ann. | Win rate |
|---|---|---|---|
| Pessimistic | -42.5% | -10.5% | 14.8% |
| Base | 8.3% | 1.6% | 20.9% |
| Optimistic | 73.5% | 11.6% | 26.8% |
5. Upside scenario vs. paper accounting
5.06× multiple; ~50.0% annualized (assuming exit in year 4).
Conditional "profitable exit succeeds" scenario for contrast (not an expected value; occurs with only ~20.91% probability).
Year-5 survival rate ≈ 67.8%.
Paper basis: counts companies still alive in year 5 at a marked valuation as "value" — a non-cashable paper figure. Official return figures never use this basis.
Go-To-Market (GTM)
Google 搜索广告精准投放
与眼科诊所合作联营
SEO 优化主流健康平台
Competition
Zocdoc — 仅预约,无 AI 问诊与健康档案
WebMD Symptom Checker — 非专科、无预约与自动化服务
Roadmap
- 上线 AI 问诊与预约核心功能
- 扩展 SEO 与诊所合作
- 上线健康档案与提醒订阅
- 持续迭代模型与自动化运维
Team & Organization
全流程自动化,无需人工运营,仅合规监督。
获客 — Google Ads + SEO,流量归集至 AI 着陆页(ChatGPT API)
交付 — AI 问诊(GPT-4o),自动症状分级与建议(专病模型)
预约 — 与医生预约系统 API 对接(Zocdoc/OpenTable Health)
客服 — AI 聊天机器人(Dialogflow)自动解答与跟进
收款 — Stripe 自动账单与支付,无需人工介入
运维 — 自动监控(Datadog)、AI 故障自愈(AWS Lambda)
Risks & Mitigations
| Risk | Mitigation |
|---|---|
| AI 误判健康风险 | 仅给出建议,明确提示非诊断 |
| 数据泄露 | 全程加密,定期安全审计 |
| 用户增长不及预期 | 优化广告投放,增加合作渠道 |
| 合规政策变化 | 持续法律监控,灵活调整产品 |
The Ask
Methodology & Sources
All hard financial conclusions are computed by a deterministic model from public, verifiable benchmark data; the AI only writes qualitative narrative and constrained operating assumptions. Out-of-range assumptions are auto-corrected (see above). Returns always use the cash-realized basis.
- China startup 1-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
Over the past decade, ~92% of newly founded Chinese companies survived their first year. - China startup 3-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
3-year survival ≈76.0% for 2014–2023 cohorts (annual attrition 8.2% / 9.4% / 6.4%). - China startup 5-year survival (interpolated): Interpolated estimate (geometric, between y3 = 0.76 and y10 = 0.503) (2024-05) · Source link
The report gives no direct 5-year figure; constant-hazard geometric interpolation between years 3 and 10 yields ≈67.5%, explicitly labelled an interpolated estimate. - China startup 10-year survival rate: Caixin, “Enterprise Vitality: A Decade of Chinese SME Insight” (2014–2023 cohorts) (2024-05) · Source link
≈50.3% of companies survive to year ten. - Average Chinese SME lifespan: People’s Bank of China report (widely cited by Chinese media) (2019-06) · Source link
Average Chinese SME lifespan ≈3 years (US ≈8 years, Japan ≈12 years). - Share of VC capital realizing <1x: Correlation Ventures — “Venture Capital, We’re Still Not Normal” (2010s decade (realized)) · Source link
≈37% of invested capital realized <1x (a loss); by deal count, roughly half of deals lose money. - Share of VC capital realizing ≥10x: Correlation Ventures (2010s decade (realized)) · Source link
Less than 4% of invested capital realizes ≥10x (the power-law tail). - VC return power law: Correlation Ventures — “The 80/20 Rule for U.S. Venture? Not Exactly.” (2010s decade) · Source link
Returns are highly right-skewed; a small number of winners contribute most of the profits. - Exit MOIC distribution (calibrated): Calibration: Correlation Ventures realized-return shape + online-asset M&A multiples (Empire Flippers / FE International / Acquire.com, 2026) (2026) · Source link
MOIC distribution conditional on a realized cash liquidity event (M&A / secondary / buyback); upside is compressed for small online assets (rarely >25x). Bucket probabilities sum to 1. - Annual exit-realization hazard (assumption): Documented assumption: median VC exits take ~5–8 years; small online assets transact faster via Acquire.com / Empire Flippers / FE International; calibrated so the cumulative 5-year exit probability ≈40% conditional on survival. (2026) · Source link
Cumulative L(t) = 1-(1-h)^t; h = 0.097 → L(5) ≈ 0.40. Explicitly labelled an assumption and stress-tested in the sensitivity analysis. - Micro-SaaS ARR multiple: CT Acquisitions / Empire Flippers / Acquire.com market observations (2026) · Source link
Micro-SaaS (<$1M ARR) typically trades at 2.5–4x ARR. - Micro-SaaS SDE multiple: FE International / Empire Flippers (2026) · Source link
Typically 4–6x seller discretionary earnings (SDE); assets with low owner-dependency fetch the high end. - Trend annualization factor (model assumption): Documented model assumption: trending interest decays in pulses; annual topic interest ≈ 30 peak-day equivalents (2026)
Google Trends volumes are peak-day buckets; annual topic searches ≈ peak-day volume × 30. Explicitly a disclosed model assumption, bounded by the reach limits below. - Capture share (model assumption): Documented model assumption: a focused niche site captures ~1% of annual topic search interest at maturity (2026)
Derived conservatively from SERP click-share distributions (~28% at #1, ~7% at #5, <1% on page 2); modulated ±50% by data-driven persistence/intent scores. - Reachable-user bounds (model constraint): Documented model constraint: year-3 reachable users are saturation-compressed into [20k, 600k] (2026)
Lower bound = minimum viable niche audience; upper bound = realistic single-niche-site capacity ceiling. Applied via a saturating function, not a hard clamp. - Zero-human fixed ops base (model assumption): Documented model assumption: hosting/compliance/model-subscription/monitoring base ramps $60k → $90k → $120k over years 1-3 (2026)
No payroll (zero-human company); includes outsourced legal/finance and exception-handling budget. - Per-active-user marginal cost (model assumption): Documented model assumption: ~$0.8 per active user per year for inference + infrastructure (2026)
Estimated for lightweight AI workflows with caching and batching. - USD/CNY exchange rate: Recent approximate CNY-per-USD rate (used for conversion; updated as needed) (2026) · Source link
Exchange rates fluctuate; converted figures are approximations as of the stated date. - Seed-round equity dilution: Industry norm: a single seed round typically dilutes 10%–20% (2026) · Source link
Baseline 12%; used to convert enterprise-level exit value into the seed investor’s share. - Early-stage venture discount rate: Early-stage VC required rates of return are typically 30%–60% (high risk premium) (2010s) · Source link
Used for risk-adjusted discounting; baseline 35%.